

# Corporate Action Notice



July 21, 2020

## Rights Offer

**BioNTech SE**

**ADS CUSIP:** 09075V102

**ADS ISIN:** US09075V1026

**ADS Ticker Symbol:** BNYX

**Ratio (ADS: Underlying Shares):** 1:1

BioNTech SE ("BioNTech") announced today that it intends to commence a rights offering in which holders of American Depositary Shares ("ADSs") as of the ADS Record Date (as defined below) will receive rights which will entitle such holder to subscribe for new ADSs ("ADS Rights"). Each ADS is equal to one (1) ordinary share. Fractional ADS rights will not be issued. The ADS Rights will not be listed for trading and are non-transferable.

Additional details about the planned rights offering will be announced on or following July 22, 2020, including the expiration time of the ADS exercise period, the ADS rights distribution ratio and the ADS subscription price. To validly subscribe for new ADSs, holders of ADSs will need to deposit with the ADS rights agent such ADS subscription payment for each new ADS subscribed for.

The details of the offer are as follows:

- ADS Record Date: **5:00 p.m. (New York City time) on July 24, 2020**
- The ADS exercise period will begin on July 28, 2020.
- The ADS Rights are non-transferable.
- Oversubscription Rights: Not applicable.
- Guarantee Period: Not applicable.
- The exercise of ADS Rights is irrevocable and may not be cancelled or modified.
- Any ADS Rights that are unexercised following the expiration of the ADS exercise period will expire and have no further value.

Information Agent: Georgeson LLC, phone number 1-888-219-8320 (U.S.) and 1-781-575-2137 (International) toll free.

A form letter with subscription instructions will be sent to registered holders of ADSs and made available to beneficial owners of ADSs as soon as practicable on or after the ADS Record Date and is also available by contacting the Information Agent.

The rights offering will be made to holders of securities only by means of a prospectus. A copy of the prospectus, when available, may be obtained from the Information Agent or by visiting the EDGAR system of the SEC at its website at [www.sec.gov/edgar.shtml](http://www.sec.gov/edgar.shtml). A registration statement on Form F-1 relating to the proposed sale of ordinary shares and ADSs in the anticipated rights offering (the "Registration Statement") has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. The ordinary shares and ADSs may not be sold, nor may offers to buy be accepted, prior to the time the Registration Statement becomes effective. This notice shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

To learn more about DRs, please contact [DRBrokerSolutions@bnymellon.com](mailto:DRBrokerSolutions@bnymellon.com) or visit our website at [adrbnymellon.com](http://adrbnymellon.com).

**PLEASE SEE INVESTOR DISCLOSURE ON LAST PAGE.**

## Investor Disclosure

This notice and the information and data provided herein are provided for general informational purposes only. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data. BNY Mellon does not undertake any obligation to update or amend this notice or any information or data, and may change, update or amend this notice or any information or data at any time without prior notice.

BNY Mellon provides no advice, recommendation or endorsement with respect to any company or securities. No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such. We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon this notice or any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

BNY Mellon collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued. From time to time, BNY Mellon may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program. BNY Mellon may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor. BNY Mellon may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. BNY Mellon may execute DR foreign currency transactions itself or through its affiliates; in such cases it acts as principal counterparty and not as agent, advisor, broker or fiduciary. BNY Mellon has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY Mellon earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY Mellon to determine DR conversion rates is available to registered Owners upon request or at [https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/asset\\_upload\\_file49220\\_197380.pdf](https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/asset_upload_file49220_197380.pdf).

This notice or any excerpt of this notice may not be copied or reproduced without the prior express written consent of BNY Mellon.

BNY Mellon is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle. BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

BNY Mellon's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY Mellon.

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY MELLON AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.